These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The effect of MPS on LAK cell growth and its cytotoxic activity against laryngeal cancer (HEP-2)].
    Author: Wang J, Zhu X, Chen J.
    Journal: Zhonghua Er Bi Yan Hou Ke Za Zhi; 1996; 31(5):283-6. PubMed ID: 9642362.
    Abstract:
    IL-2/LAK adoptive immunotherapy is one of new complementary treatments for advanced malignant tumors. This therapy has two main problems: high dose of IL-2 often causes serious side effects and it is difficult to gain enough amount of LAK cells. MPS is a new immunomodulator in cancer immunotherapy. The present study showed that, comparing with IL-2 10(6)U/L only, IL-2 2 x 10(5)U/L plus MPS 0.4mg/L was significantly more effective in activating both the growth of LAK cells and its cytotoxicity against HEP-2 cells. And the ratio of CD25 positive LAK cells cultured in this condition was also higher. This result suggests that MPS plays a role in creasing the membrane receptors of IL-2.
    [Abstract] [Full Text] [Related] [New Search]